Core Points - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., has received a renewed Drug Production License from the Hainan Provincial Drug Administration, ensuring its continued operations [1][2][3] - The previous license was set to expire on November 5, 2025, and the new license is valid until August 7, 2030 [1] - The company specializes in the production of small-volume injectables, lyophilized powder injections, raw materials, and large-volume injectables [1] Company Information - Company Name: Hainan Shuangcheng Pharmaceutical Co., Ltd. [1] - Registered Address: No. 16, Xingguo Road, Xiuying District, Haikou City [1] - Legal Representative: Wang Chengdong [1] - Quality Responsible Person: Li Yuan [1] - License Number: Qiong 20150028 [1] - Daily Supervision Management Agency: Hainan Provincial Drug Administration [1] License Details - The new Drug Production License was issued due to the impending expiration of the previous license [1] - The renewal of the license is expected to have no significant impact on the company's production and operations [1]

Core Viewpoint - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., has successfully obtained a renewed Drug Production License, ensuring its continued operations without significant impact on its business activities [1][2]. Group 1: License Details - The new Drug Production License is valid until August 7, 2030, replacing the previous license that was set to expire on November 5, 2025 [1]. - The company is located at No. 16, Xingguo Road, Xiuying District, Haikou City, with a social credit code of 9146000072122491XG [1]. - The license covers the production of small-volume injections, lyophilized powder injections, raw materials, and large-volume injections [1]. Group 2: Management and Oversight - The legal representative of the company is Wang Chengdong, with Li Jianming as the responsible person and Li Yuan as the quality manager [1]. - The daily supervision and management are conducted by the Hainan Provincial Drug Administration [1].

海南双成药业股份有限公司（以下简称"公司"）原有《药品生产许可证》 将于 2025 年 11 月 05 日到期。近日公司收到海南省药品监督管理局换发的《药 品生产许可证》，相关主要信息如下： 企业名称：海南双成药业股份有限公司 注册地址：海口市秀英区兴国路 16 号 社会信用代码：9146000072122491XG 证券代码：002693 证券简称：*ST双成 公告编号：2025-055 海南双成药业股份有限公司 关于取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 分类码：AhBhChDh 日常监督管理机构：海南省药品监督管理局 有效期至：2030 年 08 月 07 日 生产地址和生产范围：海口市秀英区兴国路 16 号；小容量注射剂（含卡式）， 冻干粉针剂（三车间，四车间），原料药，大容量注射剂**** 本次《药品生产许可证》换发是由于原许可证即将到期，新证的取得确保了 公司的正常生产经营，不会对公司生产经营产生重大影响。由于医药产品的行业 特点，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 海南双成药业股份有限公 ...

Core Viewpoint - The financial performance of Shuangcheng Pharmaceutical (002693.SZ) is deteriorating, with significant declines in revenue and profits, raising concerns about its future viability and potential delisting from the Shenzhen Stock Exchange [2][6][7]. Financial Performance - In the first half of 2025, Shuangcheng Pharmaceutical reported total revenue of 84.12 million yuan, a year-on-year decrease of 11.35% [2]. - The net profit attributable to shareholders was -18.47 million yuan, down 8.97% year-on-year, while the net profit after deducting non-recurring items was -21.02 million yuan, a decline of 18.34% [2]. - The company's cash reserves plummeted by over 70% compared to the same period last year, leaving only 4.78 million yuan, insufficient to cover even one month of operating expenses [5]. Product Performance - Revenue from peptide products, other products, and entrusted business all experienced declines in the first half of 2025, with entrusted business revenue dropping by 41.04% [2][4]. - The revenue from peptide products was 40.07 million yuan, a decrease of 3.95%, and accounted for 47.64% of total revenue, with a gross margin of 46.5%, down 13.87 percentage points from the previous year [3]. Market Challenges - The decline in gross margin is attributed to price reductions for core products, particularly the injection of thymosin alpha-1, which saw a significant drop in sales profits due to new procurement pricing [3]. - The company has faced challenges in expanding its entrusted business, with revenue from this segment only accounting for 13.90% of total revenue, and slow progress in external CMO collaborations [4]. Legal and Financial Issues - Shuangcheng Pharmaceutical has initiated legal action against Zhongrong Trust due to overdue financial products, seeking repayment of 21.05 million yuan in principal and interest [8][9]. - The company has reported cumulative losses exceeding 700 million yuan over the past nine years, raising concerns about its financial sustainability [6]. Future Outlook - The company has proposed several measures to improve performance, including increasing R&D investment, expanding sales channels, and optimizing operational processes [7]. - However, the revenue trend from 2022 to 2025 shows a consistent decline, indicating significant challenges ahead in meeting the revenue threshold to avoid delisting [7].

New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

Core Viewpoint - *ST Shuangcheng has filed a lawsuit against Zhongrong International Trust due to overdue trust products, with a total amount of 51.98479 million yuan involved, highlighting ongoing issues in the trust product market and the financial strain on companies relying on these investments [2][3][4]. Company Summary - *ST Shuangcheng has initiated legal proceedings against Zhongrong International Trust for overdue payments related to two trust investments totaling 51.98479 million yuan, which includes principal and interest [2][3]. - The company invested 20 million yuan in a trust product with a 7.0% annualized expected return and 30 million yuan in another product with a 6.2% return, both of which have not been repaid as scheduled [3]. - The overdue amounts include 20 million yuan and 105.479452 thousand yuan due by September 29, 2023, and 30 million yuan and 93 thousand yuan due by October 18, 2023 [3]. - The lawsuit seeks full repayment of the overdue amounts along with interest losses calculated based on the Loan Prime Rate (LPR) [3]. Financial Impact - The overdue trust funds represent over 60% of *ST Shuangcheng's total revenue of 84.1221 million yuan for the first half of the year, exacerbating the company's financial difficulties [4][5]. - The company reported a net loss of 18.4666 million yuan in the first half of the year, which has increased compared to the previous year's loss [4][5]. - The inability to access these funds may hinder the company's ability to procure raw materials, invest in research and development, or repay debts, potentially leading to a chain reaction of financial issues [5]. Industry Context - Since 2023, multiple companies have faced similar issues with Zhongrong Trust products, indicating a broader trend of overdue payments affecting various firms [2][6]. - The trust industry is currently undergoing significant challenges, with many companies experiencing overdue products and financial strain, prompting a reevaluation of the risks associated with trust investments [10][11]. - The trend of companies relying on trust products has been declining due to regulatory changes and deteriorating asset quality, with a notable decrease in the number of companies investing in trust products in recent years [9][10].

Company Dynamics - Recently, *ST Shuangcheng (002693.SZ) announced that it has filed a lawsuit in Harbin, Heilongjiang Province, due to overdue payments on financial products purchased from Zhongrong International Trust Co., Ltd., involving an amount of 51.98479 million RMB [2] - The company invested a total of 50 million RMB in Zhongrong Trust's financial products in two transactions in September 2022 and April 2023, but these products have all become overdue, with only partial interest payments made [2] - Zhongrong Trust announced on September 15, 2023, that it is facing payment difficulties for some of its trust products due to multiple internal and external factors, and has engaged Jianxin Trust and CITIC Trust for professional management services [2] Additional Information - Zhongrong Trust's major shareholder, Jingwei Textile Machinery (000666.SZ), has recently submitted an application for delisting to the Shenzhen Stock Exchange [3] - Zhongrong Trust was established in 1987 and has not disclosed annual reports for three consecutive years since 2022 [3]

证券代码：002693 证券简称：*ST双成 公告编号：2025-053 海南双成药业股份有限公司 关于公司提起诉讼的公告 二、本次诉讼的基本情况 1、诉讼受理日期：2025 年 8 月 4 日 1、案件所处的诉讼阶段：法院已受理，尚未开庭审理。 2、公司所处的当事人地位：原告 3、涉案金额：51,984,794.52 元人民币 4、对公司损益产生的影响：本次诉讼案件尚未开庭审理和判决，对公司本 期利润或期后利润的具体影响具有不确定性。 一、本次诉讼受理的基本情况 海南双成药业股份有限公司（以下简称"公司"）分别于 2022 年 9 月和 2023 年 4 月购买中融国际信托有限公司（以下简称"中融信托"）理财产品合计 5,000 万元。上述理财产品均已逾期，仅兑付部分利息款，剩余本息尚未兑付。具体详 见公司于 2023 年 9 月 29 日、2023 年 10 月 21 日披露的《关于部分理财产品逾 期兑付的风险提示公告》（公告编号：2023-060、2023-061）。 近日，公司收到黑龙江省哈尔滨市南岗区人民法院传票等相关资料，公司因 营业信托纠纷对中融信托提起诉讼。截至本公告披露日，上述案件法院已受理 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 证券代码：002693 证券简称：*ST双成 公告编号：2025-054 海南双成药业股份有限公司 关于为控股子公司提供担保暨关联交易的进展公告 海南双成药业股份有限公司（以下简称"公司"）分别于 2025 年 7 月 14 日 召开第五届董事会第十九次会议及 2025 年 7 月 31 日召开 2025 年第一次临时股 东会，审议通过了《关于为控股子公司提供担保暨关联交易的议案》。公司控股 子公司宁波双成药业有限公司（以下简称"宁波双成"）因日常经营需要，拟向 中国建设银行股份有限公司宁波杭州湾新区支行（以下简称"建设银行"）申请 4,000 万元借款。公司和公司控股股东海南双成投资有限公司（以下简称"双成 投资"）拟为宁波双成向建设银行借款分别提供连带责任担保，担保期限为主合 同下的债务履行期届满之日起三年。具体内容详见 2025 年 7 月 15 日刊登于巨潮 资讯网的《关于为控股子公司提供担保暨关联交易的公告》（公告编号：2025-045）。 二、担保进展情况 近日，公司及双成投资分别与 ...

New Stock Issuance - The new stock issuance for Zhigao Machinery (证券代码: 920101) is priced at 17.41 CNY per share, effective from August 5, 2025[1] - China Heavy Industry (证券代码: 601989) has a cash option declaration period from August 13, 2025[1] - China Shipbuilding (证券代码: 600150) has a buyback request period from August 13 to August 15, 2025[1] Offer and Acquisition Periods - Shenkou Co., Ltd. (证券代码: 002633) has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly (证券代码: 300326) has a tender offer period from July 17 to August 15, 2025[1] - Happiness Blue Ocean (证券代码: 300528) has a significant announcement on July 30, 2025[1] Market Volatility - There are reports of severe abnormal fluctuations for Tibet Tourism (证券代码: 600749) as of July 31, 2025[1] - ST Suwu (证券代码: 600200) also reported significant volatility on July 30, 2025[1] - The stock of ST YaTai (证券代码: 000691) is under observation for abnormal trading activities as of August 5, 2025[1]